Plant Name: Dryopteris crassirhizoma
Taxonomic Information:
Plant ID: NPO536
Plant Latin Name: Dryopteris crassirhizoma
Taxonomy Genus: Dryopteris
Taxonomy Family: Dryopteridaceae
Plant External Links:
NCBI TaxonomyDB:
97234
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMMedicinal Functions:
Analgesic; Depurative; Haemostatic; Resolvent; Vermifuge
Geographical Distribution:
China
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; | |
| NPSR1; | |
| TDP1; BLM; PIK3CA; PIK3CB; HSD11B1; AKR1B10; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; NQO2; POLB; | |
| CDC25B; | |
| AURKB; MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; | |
| CA12; CA9; CA14; CA7; | |
| ESR1; | |
| NR1H4; | |
| TYR; PTGS2; | |
| AHR; | |
| LMNA; FABP3; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.116E-08 | 2.095E-05 | CA12, CA14, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.379E-08 | 2.943E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 9.544E-08 | 6.298E-05 | ALOX12, AURKB, AXL, CDK1, FFAR4, IGF1R, KDR, LMNA, NR1H4, PIK3CA, PIM1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.357E-07 | 8.206E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.402E-07 | 1.276E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, NOX4, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.941E-07 | 3.300E-04 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.773E-07 | 3.547E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 1.342E-06 | 4.790E-04 | IGF1R, PIK3CA, PIK3CB |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.016E-06 | 6.361E-04 | CA12, CA14, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0010243; response to organonitrogen compound | 2.489E-06 | 7.324E-04 | BLM, CDK1, FABP3, FFAR4, FLT3, IGF1R, NOX4, NR1H4, PTGS2, TYR |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 2.535E-06 | 7.361E-04 | ALOX15, AXL, NOX4, NR1H4, PIK3CA, PIK3CB, POLB, PTGS2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.181E-06 | 1.047E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.181E-06 | 1.047E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.522E-06 | 1.106E-03 | ALOX12, ALOX15, PTGS2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 6.858E-06 | 1.493E-03 | BLM, CYP1A1, CYP1B1, ESR1, FLT3, NOX4, PTGS2 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 7.489E-06 | 1.583E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.066E-05 | 2.211E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.253E-05 | 2.414E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.253E-05 | 2.414E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.253E-05 | 2.414E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.253E-05 | 2.414E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.416E-05 | 2.704E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.465E-05 | 2.733E-03 | AXL, KDR, PIK3CA, PIK3CB |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.488E-05 | 2.747E-03 | AXL, MET, NOX4, PIK3CA, PIK3CB |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 2.226E-05 | 3.816E-03 | FABP3, FFAR1, NR1H4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.502E-05 | 4.097E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.502E-05 | 4.097E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 3.927E-05 | 5.857E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 4.165E-05 | 6.087E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 4.165E-05 | 6.087E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 5.040E-05 | 7.173E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.602E-05 | 7.819E-03 | CA12, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 6.239E-05 | 8.438E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.239E-05 | 8.438E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0008289; lipid binding | 6.219E-05 | 8.438E-03 | ALOX15, AXL, CYP3A4, ESR1, FABP3, FFAR1, FFAR4, NR1H4 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 6.592E-05 | 8.752E-03 | ALOX12, CDC25B, CDK1, ESR1, FLT3, IGF1R, KDR, PIM1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 7.609E-05 | 9.921E-03 | ALOX15, CDK1, FFAR4, FLT3, KDR, NOX4, PIK3CB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.621E-09 | 2.059E-07 | HSD11B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.898E-08 | 1.555E-06 | HSD17B2, CYP1A1, CYP1B1, PTGS2, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.354E-08 | 8.600E-07 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.358E-07 | 8.529E-06 | HSD11B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.464E-06 | 3.098E-05 | PIK3CA, CDK1, PIK3CB, CDC25B, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.924E-06 | 5.304E-05 | PIK3CA, KDR, PIK3CB, ESR1, MET, IGF1R |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.203E-08 | 1.356E-06 | CA12, CA7, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 5.018E-06 | 7.967E-05 | PIK3CA, FLT3, PIM1, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 6.592E-06 | 9.302E-05 | PIK3CA, KDR, PIK3CB, PTGS2 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.150E-05 | 2.276E-04 | HSD11B1, AKR1B10, HSD17B2, CYP1A2, ALOX15, CYP1A1, ALOX12, PTGS2, CYP3A4, TYR, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.210E-05 | 1.397E-04 | PIK3CA, PIK3CB, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 9.599E-06 | 1.219E-04 | PIK3CA, FLT3, PIK3CB, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.559E-05 | 2.370E-04 | PIK3CA, PIM1, CYP1B1, PTGS2, MET, CDC25B |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.937E-05 | 4.180E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 6.073E-05 | 4.820E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 8.579E-05 | 6.053E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.277E-04 | 8.538E-04 | PIK3CA, FLT3, PIK3CB, PTGS2, MET, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 6.956E-05 | 5.196E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.909E-04 | 1.212E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 5.640E-04 | 2.558E-03 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.971E-04 | 1.572E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.837E-04 | 1.572E-03 | PIK3CA, PIK3CB, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.583E-04 | 1.562E-03 | ALOX15, ALOX12, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.612E-05 | 2.370E-04 | CYP1A2, ALOX15, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 7.338E-04 | 3.061E-03 | POLB, PIK3CA, CDK1, PIK3CB |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.017E-04 | 1.962E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 3.108E-04 | 1.579E-03 | PIK3CA, PIK3CB, MET |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.971E-04 | 1.572E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 7.471E-04 | 3.061E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 9.882E-04 | 3.801E-03 | PIK3CA, ALOX12, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.078E-03 | 3.913E-03 | PIK3CA, PIM1, PIK3CB |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 5.081E-04 | 2.390E-03 | PIK3CA, PIK3CB, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 6.761E-04 | 2.961E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 8.758E-04 | 3.476E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.018E-03 | 3.801E-03 | PIK3CA, PIK3CB, ESR1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.379E-03 | 4.734E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.141E-03 | 4.026E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.453E-03 | 4.854E-03 | ALOX15, ALOX12, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.687E-03 | 5.494E-03 | PIK3CA, PIK3CB, ESR1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.744E-03 | 8.145E-03 | PIK3CA, LMNA, PIK3CB |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 1.944E-03 | 6.172E-03 | PIK3CA, PIK3CB, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.373E-03 | 7.351E-03 | PIK3CA, PIK3CB, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.857E-03 | 8.245E-03 | PIK3CA, PIK3CB, IGF1R |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 2.758E-03 | 8.145E-03 | PIK3CA, PIK3CB |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; TYR; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; FLT3; PTGS2; PIK3CB; NQO2; CDC25B; CA9; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; PIK3CB; CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; FFAR1; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CA9; |
| NA: NA | GIST | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTGS2; FFAR1; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
